Loss of Sense of Smell and Taste May Last up to 5 Months After COVID-19

American Academy of Neurology (AAN)

EMBARGOED FOR RELEASE UNTIL 4 P.M. ET, MONDAY, FEBRUARY 22, 2021

 

Newswise — MINNEAPOLIS - People with COVID-19 may lose their sense of smell and taste for up to five months after infection, according to a preliminary study released today, February 22, 2021, that will be presented at the American Academy of Neurology’s 73rd Annual Meeting being held virtually April 17 to 22, 2021.

While COVID-19 is a new disease, previous research shows that most people lose their sense of smell and taste in early stages of the illness,” said study author Johannes Frasnelli, M.D., of the University of Quebec at Trois-Rivieres in Canada. “We wanted to go further and look at how long that loss of smell and taste lingers, and how severe it is in people with COVID-19.”

The study involved 813 health care workers who tested positive for COVID-19. Each person completed an online questionnaire and home test to evaluate their sense of taste and smell on average five months after diagnosis. They rated their senses of taste and smell on a scale from 0 to 10. Zero meant no sense at all, and 10 meant a strong sense of taste or smell. Researchers found the average person did not regain their sense of smell entirely.

A total of 580 people lost their sense of smell during the initial illness. Of this group, 297 participants, or 51%, said they still had not regained their sense of smell five months later, while 134 participants, or 17%,  had persistent loss of smell when evaluated with the home test. On average, people ranked their sense of smell at a seven out of 10 after the illness, compared with a nine out of 10 before they had gotten sick.

A total of 527 participants lost their sense of taste during the initial illness.­ Of this group 200 people, or 38%, said they still had not regained their sense of taste five months later, while 73 people, or 9%, had persistent loss of taste when evaluated with the home test. On average, people ranked their sense of taste at an eight out of 10 after the illness, compared with a nine out of 10 before they had gotten sick.

“Our results show that an impaired sense of smell and taste may persist in a number of people with COVID-19,” Frasnelli said. “This emphasizes the importance of following up with people who have been infected, and the need for further research to discover the extent of neurological problems associated with COVID-19.”

Limitations of the study include the subjective nature of the smell and taste ratings and the single timepoint at which data was collected.  

The study was supported by the Foundation of the University of Quebec at Trois-Rivieres and the Province of Quebec.

Learn more about COVID-19 at BrainandLife.org, home of the American Academy of Neurology’s free patient and caregiver magazine focused on the intersection of neurologic disease and brain health. Follow Brain & Life® on Facebook, Twitter and Instagram.

When posting to social media channels about this research, we encourage you to use the American Academy of Neurology’s Annual Meeting hashtag #AANAM.

The American Academy of Neurology is the world’s largest association of neurologists and neuroscience professionals, with over 36,000 members. The AAN is dedicated to promoting the highest quality patient-centered neurologic care. A neurologist is a doctor with specialized training in diagnosing, treating and managing disorders of the brain and nervous system such as Alzheimer’s disease, stroke, migraine, multiple sclerosis, concussion, Parkinson’s disease and epilepsy.

For more information about the American Academy of Neurology, visit AAN.com or find us on Facebook, Twitter, Instagram, LinkedIn and YouTube




Filters close

Showing results

110 of 5584
Released: 7-May-2021 1:40 PM EDT
There is no evidence that vaccines could cause harm to people who have recovered from COVID-19
Newswise

An article published by Robert F. Kennedy Jr.’s anti-vaccination organization and widely shared on social media questions the need of vaccinating those who’ve already recovered from COVID-19. The article says there’s a "potential risk of harm, including death" in getting the vaccines. We report this claim as false. There is no evidence that vaccinating people who had previously had COVID is resulting in an increased risk of adverse events.

Newswise: Abbott.jpg
Released: 7-May-2021 1:00 PM EDT
FSU expert available to discuss intellectual property and COVID-19 vaccines
Florida State University

By: Bill Wellock | Published: May 7, 2021 | 11:55 am | SHARE: President Joe Biden has expressed his support for a World Trade Organization proposal to waive intellectual property rights for COVID-19 vaccines.Florida State University law professor Frederick Abbott, the Edward Ball Eminent Scholar Professor of International Law, is available to comment on international intellectual property rights and global economic issues around the proposal.

access_time Embargo lifts in 2 days
Embargo will expire: 11-May-2021 11:00 AM EDT Released to reporters: 7-May-2021 1:00 PM EDT

A reporter's PressPass is required to access this story until the embargo expires on 11-May-2021 11:00 AM EDT The Newswise PressPass gives verified journalists access to embargoed stories. Please log in to complete a presspass application. If you have not yet registered, please Register. When you fill out the registration form, please identify yourself as a reporter in order to advance to the presspass application form.

Released: 7-May-2021 11:15 AM EDT
Asthma attacks plummeted among Black and hispanic/latinx individuals during the COVID-19 pandemic
Brigham and Women’s Hospital

Asthma attacks account for almost 50 percent of the cost of asthma care which totals $80 billion each year in the United States

access_time Embargo lifts in 2 days
Embargo will expire: 11-May-2021 11:00 AM EDT Released to reporters: 7-May-2021 10:40 AM EDT

A reporter's PressPass is required to access this story until the embargo expires on 11-May-2021 11:00 AM EDT The Newswise PressPass gives verified journalists access to embargoed stories. Please log in to complete a presspass application. If you have not yet registered, please Register. When you fill out the registration form, please identify yourself as a reporter in order to advance to the presspass application form.

Released: 7-May-2021 9:00 AM EDT
Navigating the COVID-19 crisis to prevent pressure injuries: Learning health system helped one hospital adapt and update care in real time
Wolters Kluwer Health: Lippincott

Early in the COVID-19 pandemic, healthcare systems scrambled to modify patient care processes – particularly when it came to strategies aimed at reducing the risk of hospital-related complications. A look at how one hospital applied its learning health system (LHS) framework to respond to a COVID-19-related increase in hospital-acquired pressure injuries (HAPIs) is presented in the May/June Journal for Healthcare Quality (JHQ), the peer-reviewed journal of the National Association for Healthcare Quality (NAHQ). The journal is published in the Lippincott portfolio by Wolters Kluwer.

Newswise: Ultra-Fast COVID-19 Sensor Invented at Texas Tech Gets Boost Into International Markets
Released: 7-May-2021 8:55 AM EDT
Ultra-Fast COVID-19 Sensor Invented at Texas Tech Gets Boost Into International Markets
Texas Tech University

EviroTech LLC announced today (May 7) a $4 million investment into the company by 1701 Ventures GmbH of Göttingen, Germany, which will allow EviroTech to complete the final design, production startup and market introduction of its Ultra-Fast COVID-19 detection sensor.

Released: 7-May-2021 7:05 AM EDT
Rutgers Recruiting Participants for Pfizer COVID-19 Pediatric Vaccine Clinical Trial
Rutgers University-New Brunswick

Rutgers has been selected as a clinical trial site for the global Pfizer-BioNTech research study to evaluate the efficacy of its COVID-19 vaccine in children ages 6 months to 11 years. This is the third time Rutgers has served as a COVID-19 vaccine clinical trial site for pharmaceutical companies. Last fall, it conducted trials for Moderna and Johnson & Johnson.


Showing results

110 of 5584

close
1.88694